Chinese API Market Growing Strongly, CPhI China Assisting Enterprises with the Transformation, Innovation, and Comprehensive Upgrading

Friday, January 11, 2019

As China continues to advance from a big country in pharmaceuticals to a power in pharmaceuticals, and the global economy maintains good trends, the main business income of API manufacturing in China has reached RMB 499.1 billion, growing by 14.68% year on year; and the export of APIs has reached USD 29.1 billion, growing by 13.7% year on year. Under the background of the new round of economic structure adjustment and supply-side reform, the proportion of import and export of western medicine preparations and biochemical drug products that are of higher additional value continues to increase in western medicine trade, showing that the transformation and upgrading of China’s pharmaceutical industry have taken a big step forward. The steadily progressing achievements and the unlimited potential demonstrate that China’s pharmaceutical industry is marching on a road of sustainable and healthy development.

Under such a background, the CPhI & P-MEC China 2019 organized by UBM EMEA and China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) and co-organized by Shanghai UBM Sinoexpo International Exhibition Co., Ltd. will be grandly held at Shanghai New International Expo Centre (SNIEC) on June 18-20, 2019. CPhI China will assist enterprises to write a new chapter of pharmaceuticals and develop new patterns of international market with transformation and upgrading.

AirBridgeCargo - Air frieght solutions for your Pharma ACG - Myanmar Pharma Matcon Efficently handling tablets and powders in IBC's MECO - 90 Years